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sequences, Trade-offs, Uncertainties, Risk attitude, and Linked deci-
sions (PrOACT-URL) framework and multiple criteria decision analysis
(MCDA) have been recommended by the European Medicines Agency
for structured beneﬁt-risk assessment of medicinal products under-
going regulatory review. Objective: The objective of this article was to
provide solutions to incorporate the uncertainty from clinical data
into the MCDA model when evaluating the overall beneﬁt-risk proﬁles
among different treatment options. Methods: Two statistical
approaches, the δ-method approach and the Monte-Carlo approach,
were proposed to construct the conﬁdence interval of the overall
beneﬁt-risk score from the MCDA model as well as other probabilistic
measures for comparing the beneﬁt-risk proﬁles between treatment
options. Both approaches can incorporate the correlation structure
between clinical parameters (criteria) in the MCDA model and are
straightforward to implement. Results: The two proposed approaches
were applied to a case study to evaluate the beneﬁt-risk proﬁle of anee front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2014.04.008
en@abbvie.com.
ndence to: Shihua Wen, Data and Statistical Sciencadd-on therapy for rheumatoid arthritis (drug X) relative to placebo. It
demonstrated a straightforward way to quantify the impact of the
uncertainty from clinical data to the beneﬁt-risk assessment and
enabled statistical inference on evaluating the overall beneﬁt-risk
proﬁles among different treatment options. Conclusions: The
δ-method approach provides a closed form to quantify the variability
of the overall beneﬁt-risk score in the MCDA model, whereas the
Monte-Carlo approach is more computationally intensive but can
yield its true sampling distribution for statistical inference. The
obtained conﬁdence intervals and other probabilistic measures from
the two approaches enhance the beneﬁt-risk decision making of
medicinal products.
Keywords: multiple criteria decision analysis (MCDA), probabilistic
sensitivity analysis, regulatory decision making, structured beneﬁt-
risk assessment of medicinal products.
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A structured beneﬁt-risk assessment of medicinal products is not a
new concept. It was initially proposed or appeared in the scientiﬁc
literature more than 20 years ago [1–3]. During the past decade,
however, a structured framework for beneﬁt-risk assessment, as
well as various qualitative and quantitative methods, has become
an emerging research topic among both regulatory and pharma-
ceutical industries around the world. In 2005, the Pharmaceutical
Research and Manufacturers of America initiated the Beneﬁt-Risk
Action Team (BRAT) and proposed the BRAT framework for
structured beneﬁt-risk assessment. The BRAT framework was
ﬁnalized in 2010, and several global pharmaceutical member
companies in Pharmaceutical Research and Manufacturers of
America have piloted the BRAT framework since then [4–6]. At
the end of 2011, the work of the BRATwas transferred to the Center
for Innovation in Regulatory Science, an independent research-based institution in the United Kingdom, whose objective is to
promote scientiﬁc making and best practice in global regulatory
affairs [7]. Currently, the Center for Innovation in Regulatory
Science is devoted to developing the Uniﬁed Methodologies for
Beneﬁt-Risk Assessment framework and piloting its structured
beneﬁt-risk assessment proforma template among regulatory
authorities and pharmaceutical companies [8,9]. The Center for
Drug Evaluation and Research of the U.S. Food and Drug Admin-
istration initiated its own effort on a structured beneﬁt-risk frame-
work in 2009. In 2010, the Food and Drug Administration/Center for
Drug Evaluation and Research proposed a ﬁve-grid beneﬁt-risk
framework that includes ﬁve decision factors—Analysis of Con-
dition, Unmet Medical Need, Beneﬁt, Risk, and Risk Management—
and an overall Beneﬁt-Risk Summary and Assessment. This frame-
work will be incorporated into Center for Drug Evaluation and
Research Standard Operating Procedures and is planned to be
rolled out in the upcoming Prescription Drug User Fee Act V [10–12].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
es, AbbVie, Inc., Building AP9A-LL, 1 North Waukegan Road, North
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toward structured beneﬁt-risk assessment, the EuropeanMedicines
Agency (EMA), in particular, started a large research project in 2008
called the Beneﬁt-Risk Methodology Project. The main objective of
this project is the development and testing of tools and processes
for balancing multiple beneﬁts and risks, which can be used as an
aid to informed, science-based regulatory decisions about medic-
inal products [13]. As of January 1, 2014, four out of ﬁve work
packages (WPs) in this EMA Beneﬁt-Risk Methodology Project have
been published. These work packages summarized the current
practice of beneﬁt-risk assessment in the European Union regu-
latory network (WP1), reviewed more than 20 qualitative and
quantitative beneﬁt-risk assessment methods (WP2), recom-
mended the eight-step Problem formulation, Objectives, Alterna-
tives, Consequences, Trade-offs, Uncertainties, Risk attitude, and
Linked decisions (PrOACT-URL) framework as well as the multiple
criteria decision analysis (MCDA) for structured beneﬁt-risk assess-
ment with several ﬁeld tests (case studies) (WP3, WP4). The overall
experience from the ﬁeld tests demonstrated the usefulness of the
MCDA approach and the PrOACT-URL framework in determining
the beneﬁt-risk balance of a medicinal product. As an extension to
the EMA Beneﬁt-Risk Methodology Project, the Innovative Medi-
cines Initiative - Pharmacoepidemiological Research on Outcomes
of Therapeutics by a European Consortium (IMI-PROTECT), a multi-
national consortium consisting of 34 public and private partners
coordinated by the EMA, has conducted its research stream (IMI-
PROTECT Work Programme 5) and published its ﬁnal recommen-
dation report for the methodology and visualization techniques to
be used in the assessment of beneﬁt and risk of medicines [14,15].
Among the PROTECT beneﬁt-risk ﬁnal report and case studies, the
MCDA approach is perhaps one of the most popular quantitative
beneﬁt-risk assessment tools [16].
The MCDA, ﬁrst introduced in 1976 by Keeney and Raiffa, has
been used recently by both regulatory authority and pharmaceutical
companies to perform beneﬁt-risk assessment of medicines [17–25].
It naturally ﬁts into the PrOACT-URL framework but is independent
with any qualitative beneﬁt-risk assessment or decision-making
framework. The MCDA brings together evaluations of different
decision options on multiple criteria into one overall evaluation
through scoring and weighting [13, EMAWP2]. Scoring is to quantify
each criterion into a common scale (called preference value,
preference score, or simply utility) for measuring the value of
decision options. Weighting is to ensure that the units of value on
all the criteria are comparable so that they can be combined into
one overall scale (called overall beneﬁt-risk score). For our beneﬁt-
risk assessment of medicinal products setting, the decision options
usually refer to the medical treatment options under evaluation/
comparison (e.g., control vs. investigational/experimental drug) and
the criteria usually refer to the beneﬁts (favorable effects) and risks
(unfavorable effects) of taking the treatments, such as the improve-
ment in the health condition and the rate of serious adverse events.
The MCDA addresses the problem of comparing beneﬁts and
risks of different decisions (i.e., different treatment options or
medicinal products in our setting) by providing a common unit of
value so that the added value of favorable effects can be
compared with the loss of value from unfavorable effects. The
obtained overall beneﬁt-risk score from a deterministic analysis,
however, usually reﬂects only the average scenario (a point
estimate) without quantifying the variability of such quantity.
Because many uncertainties may be involved in the beneﬁt-risk
assessment, it is important to understand the variability of the
overall beneﬁt-risk score, namely, how sensitively the overall
beneﬁt-risk proﬁle will be affected by underlying uncertainties.
There are generally two types of uncertainty in MCDA modeling
when assessing the beneﬁt-risk balance of different treatment
options. One is from the MCDA model itself and is usually
subjective in nature. For instance, different value functions,weights, or criteria selections will certainly have an impact on
the comparison of the overall beneﬁt-risk proﬁles of different
treatment options. The other type of uncertainty arises from the
clinical data and is usually objective. For instance, given a ﬁxed
MCDA model in which the criteria, the value functions of each
criterion, and the weights of each criterion are settled, the
variability of the overall beneﬁt-risk proﬁle can be affected by
the data extracted from clinical trials and the variation in the
clinical data [26]. For instance, the instinct variation or different
data pooling strategies in an integrated analysis will obviously
affect the variability of the data. The ﬁrst type of uncertainty
usually can be quantiﬁed by a deterministic sensitivity analysis
in which different value functions or weights of the criteria are
used to see how the overall beneﬁt-risk balance may change
because of varied MCDA model setting. To quantify the second
type of uncertainty, probabilistic modeling may be used to
incorporate the variability of clinical data into the MCDA model.
In this article, we propose two probabilistic approaches (the δ-
method approach and the Monte-Carlo approach) to incorporate
the variability of clinical data into the MCDA modeling. The merit
of the δ-method approach is that it provides a closed-form solution
to quantify the variability by imposing an asymptotically normal
distribution to the overall beneﬁt-risk score from the MCDA model.
Compared with simulation-based methods, the δ-method appro-
ach based on a known distributional form of the overall beneﬁt-risk
score is much simpler and less computationally intensive. How-
ever, the Monte-Carlo approach proposed in this article is one type
of simulation-based method. It uses a uniﬁed multivariate normal
sampling scheme to sample from the parameter space of the
criteria in the MCDA model so that the correlation structure of
the criteria in the MCDAmodel could be preserved. In addition, the
Monte-Carlo approach could assemble the true distribution of the
overall beneﬁt-risk score, which, in turn, would enable the compu-
tation of any desired probabilistic/statistical measures to compare
the beneﬁt-risk proﬁle of different treatment options. In the Results
section, the proposed methods were applied to a case study, and a
discussion on the performance of the proposed methods appears
in the Discussion and Conclusion section.Methods
The δ–Method Approach
Without loss of generality, we use the weighted summation form
of the MCDA as [13, WP3] follows:
s¼∑wif iðμiÞ ð1Þ
where s is the overall beneﬁt-risk score of a certain treatment
option. Usually, the higher the score, the better the beneﬁt-risk
proﬁle of the treatment. wi is the weight of the ith criterion, fi(mi) is
the corresponding value function transforming mi into a uniﬁed
scale, and mi is the true clinical mean effect (parameter), such as
the reduction in blood pressure from baseline to ﬁnal, the
response rate, or the chance of a certain adverse drug reaction
for the corresponding treatment option. Usually, the true mi is
unknown but can be substituted by its estimator, μ^i. Thus, an
estimator of s can be deﬁned by
s^¼∑wif iðμ^iÞ
s^ANðs,∇s0Γ∇sÞ ð2Þ
According to the central limit theorem and with sufﬁciently large
sample size, using the δ-method [27], s^ in Equation 2 is asymp-
totically normal, with Eðs^Þ¼s and varðs^Þ  ∇s0Γ∇s, where ∇s is the
gradient vector of s with respect to μis and Γ is the variance-
covariance matrix of μis. In practice, s is estimated by s^ and varðs^Þ
is estimated by n  ∇s^0Γ^∇s^, where ∇s^ is ∇s evaluated at μ^is, and Γ^
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among the decision criteria in the MCDA model. Thus, with a
ﬁxed, predeﬁned value function and weight set, an approximate
100(1  α)% conﬁdence interval of the overall beneﬁt-risk score
for a treatment option can be constructed as
s^zα
2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∇s^'Γ^∇s^
p
ð3Þ
where zα
2
is the upper α /2 percentile of the standard normal
distribution.
Because the distribution of the overall beneﬁt-risk score for
each treatment option can be quantiﬁed according to Equation 2,
pairwise treatment comparisons can be performed and statistical
inferences can be drawn. Assume that s^C and s^E represent the
overall beneﬁt-risk proﬁle of the control and the experimental
treatment option, respectively. The distribution of the difference
(D) of the overall beneﬁt-risk proﬁles between the two treatment
options is also asymptotically normal with mean and variance as
DANðs^Es^C,v^Eþ v^CÞ ð4Þ
An approximate 100(1  α)% conﬁdence interval of the difference
in the overall beneﬁt-risk proﬁles between the two treatment
options can be constructed as
S^ES^Czα2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
v^Eþ v^C
p
ð5Þ
And an approximate one-sided P value can be obtained by
1Φ s^Es^Cﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
v^Eþ v^C
p
 !
ð6Þ
where Φð:Þ is the cumulative distribution function of the standard
normal distribution.
A probabilistic measure for the probability that the overall
beneﬁt-risk proﬁle of the experimental treatment is better than
the control can be calculated by PrðD40Þ¼ R þ10 f ðDÞdD, where D is
the difference in the overall beneﬁt-risk scores of the two treat-
ment options under the comparison and f(D) is the density
function of D as in Equation 4.
Sometimes, it is of most interest to summarize potential
differences between treatment groups rather than provide clin-
ical results of individual treatments. In this case, the δ–method
approach still applies except that in Equation 2, the s will be
regarded as the difference in the overall beneﬁt-risk scores
between treatment options and the Γ will represent the
variance-covariance matrix of the treatment difference for the
criteria in the MCDA model. Once the distribution of the differ-
ence in the overall beneﬁt-risk proﬁle between the two treatment
options is obtained, other probabilistic or statistical measures can
be derived in a similar way.
The Monte-Carlo Approach
The Monte-Carlo approach provides an alternative to the
δ–method approach to quantify the uncertainty of the overall
beneﬁt-risk proﬁle on the basis of study-level summary statistics.
Detailed steps are provided below.1. According to the central limit theorem and given a sufﬁciently
large sample size, the sampling distribution of parameters of
the criteria in the MCDA model is asymptotically multivariate
normal with mean vector μ^ and variance-covariance matrix Γ^.
As such, multidimensional random samples from this multi-
variate normal distribution can be drawn to simulate the
results from virtual clinical trials.2. For a treatment option, generate the multidimensional ran-
dom samples (say 10,000) according to step 1, then apply the
predeﬁned value functions and weights to each set of sample
points to obtain the corresponding overall beneﬁt-risk score
according to Equation 1. This yields the true samplingdistribution (10,000 sample points) of the overall beneﬁt-risk
score s for the particular treatment option.3. Once the true sampling distribution has been obtained, the
100(1  α)% conﬁdence interval of the overall beneﬁt-risk score
for a treatment option can be constructed by its corresponding
α/2 and 1  α/2 percentiles. Other statistical measures, such as
the mean or median of the overall beneﬁt-risk score of the
particular treatment option, can be obtained as well because
the whole sampling distribution is available.4. The statistical comparison of the beneﬁt-risk proﬁle between
two treatment options can be conducted as follows:
 The 100(1  α)% conﬁdence interval of the difference of the
two overall beneﬁt-risk proﬁles can be obtained by select-
ing the α/2 and 1  α/2 percentiles of the difference of the
two simulated overall beneﬁt-risk score samples generated
in step 2.
 The probabilistic measure of Pr[overall beneﬁt-risk proﬁle of
the Experimental treatment is better than the Control] is
essentially the proportion of the difference of the two simu-
lated overall beneﬁt-risk score samples being greater than 0.
 To obtain the P value (one-sided) by using the Monte-Carlo
approach, ﬁrst, use the parameters of the control group to
simulate two sets of random samples of the overall beneﬁt-
risk scores and calculate the difference of the two sets. This
yields the sampling distribution of the difference of the two
overall beneﬁt-risk proﬁles under the null hypothesis (i.e., null
sampling distribution in which the beneﬁt-risk proﬁles of the
two treatments are equal). Then, the top rank of the difference
of the overall beneﬁt-risk scores from the observed data
(s^Es^C) among the simulated null distribution indicates the
P value of interest. For instance, if s^Es^C from the observed
data is within the top 5% of the simulated null distribution,
say, the 156th largest out of the 10,000, the P value will be
0.0156, and the beneﬁt-risk proﬁle of the experimental treat-
ment may be considered as statistically signiﬁcantly better
than the control under the common signiﬁcance level of 0.05.In case clinical results are presented in a treatment difference
format, the Monte-Carlo approach still applies, but the above listed
steps will require some minor modiﬁcations to reﬂect that the
Monte-Carlo simulation is conducted on the treatment difference
level. For obtaining the P value, because the clinical results are
presented in the treatment difference format already, simply make
the mean vector 0 to simulate the null distribution of the differ-
ence of the overall beneﬁt-risk proﬁles between two treatment
options; then, the rest of the steps in the process are the same.
Both the δ-method approach and the Monte-Carlo approach
proposed in this article are available in R programs, (see Appendix
in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2014.04.008) which can be applied easily.Results
To illustrate the proposed methods, a case study is conducted
using the data from the EMA beneﬁt-risk methodology work
package 3 report: Field tests (WP3) [13]. The ﬁeld tested drugs
were all real products under the review of the Committee for
Medicinal Products for Human Use at that time. Because of
conﬁdentiality reasons, however, detailed information of those
data could not be given and “drug X” was used for illustration
purposes in the WP3. We used the name drug X for our case study
here as well. The case study is to assess the overall beneﬁt-risk
proﬁle of drug X to be used in combination with methotrexate
(MTX). There are three treatment options, namely, placebo þ
MTX, drug X 200 mg þ MTX, and drug X 400 mg þ MTX. The
multiple criteria for the beneﬁt-risk consideration in the MCDA
Table 1 – Effect table (clinical data for each criterion in the MCDA model).
Criteria Placebo þ MTX Drug  200 mg
þ MTX
Drug  400 mg
þ MTX
Relative
weight
Measure* Size† Measure Size Measure Size
Beneﬁt (favorable effects)
ACR 20 (%): Proportion of patients achieving ACR
20 at week 24
11.7 100 58.2 100 59.6 100 40
ACR 50 (%): Proportion of patients achieving ACR
50 at week 24
5.8 100 34.8 100 36.6 100 70
ACR 70 (%): Proportion of patients achieving ACR
70 at week 24
2.4 100 18.8 100 16.1 100 100
mTSS (change  SD): Mean amount of progression
of joint damage in hands and feet at week 52
2.8  7.8 97 0.4  5.7 93 0.0  4.8 95 100
Infections (no./100 patient-years): Proportion of
patients experiencing infections and
infestations
72.13 80 79.88 85 76.62 91 20
SAEs (no./100 patient-years): Proportion of
patients experiencing musculoskeletal and
connective tissue disorders
57.05 71 28.39 77 25.88 83 30
Risk (unfavorable effects)
Deaths (%): Proportion of patient deaths 0.15 100 0.42 99 0.97 97 100
Tuberculosis (number): Number of patients
contracting tuberculosis
0 98 5 100 28 99 30
Malignancies (%): Proportion of patients
developing at least one malignancy
0.9 100 1.9 98 1.4 99 50
ACR, American College of Rheumatology; B-R, beneﬁt-risk; EMA, European Medicines Agency; MCDA, multiple criteria decision analysis; mTSS,
Medial Tibial Stress Syndrome; MTX, methotrexate; SAEs, serious adverse events.
* Measure columns are the real clinical data extracted from Table 3 in the EMA B-R work package 3.
† The numbers in the size columns are either the sample size (number of patients) or the total drug exposure (patient-year) of each
corresponding treatment group. Those numbers are hypothetical and for illustration purpose only.
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ACR 70, and Medial Tibial Stress Syndrome (mTSS) for beneﬁts
(favorable effects) and infections, serious adverse events, deaths,
tuberculosis, and malignancies for risks (unfavorable effects).
Summary statistics for the clinical data and the corresponding
weights for each criterion in the MCDA model are presented in
Table 1. Note that the clinical measurement data included in
Table 1 were extracted from Table 3 in the WP3. Because Table 3
of the WP3 did not provide sample size information, the sample
size (number of patients) and the total drug exposure (patient-Table 2 – Correlation matrix among criteria in the MCDA
same for the three treatment options).
Correlation structure ACR 20 ACR 50 ACR 70 mTSS
Beneﬁt
ACR 20 (%) 1 0.943 0.882 0.816
ACR 50 (%) 0.943 1 0.935 0.866
ACR 70 (%) 0.882 0.935 1 0.926
mTSS (change  SD) 0.816 0.866 0.926 1
Risk
Infections (no./100
patient-years)
0.745 0.791 0.845 0.913
SAEs (no./100 patient-
years)
0.667 0.707 0.756 0.816
Deaths (%) 0.577 0.612 0.655 0.707
Tuberculosis
(number)
0.471 0.5 0.535 0.577
Malignancies (%) 0.333 0.354 0.378 0.408
ACR, American College of Rheumatology; MCDA, multiple criteria deci
adverse events.years) data in the table were artiﬁcially created and used for
illustration purposes only. The relative weight column lists the
weights that were derived on the basis of results in the WP3. As a
key component in MCDA modeling, the weights represent the
relative importance of each criterion and ensure the equivalence
of the units of weighted preference scores across different
criteria. The clinical parameters of the criteria in the case study
were in different types, such as proportion and counts. With
sufﬁciently large sample size, however, the normal approxima-
tion can be used to approximate the distribution of each non-model (the correlation structure is assumed to be the
Infections SAEs Deaths Tuberculosis Malignancies
0.745 0.667 0.577 0.471 0.333
0.791 0.707 0.612 0.5 0.354
0.845 0.756 0.655 0.535 0.378
0.913 0.816 0.707 0.577 0.408
1 0.894 0.775 0.632 0.447
0.894 1 0.866 0.707 0.5
0.775 0.866 1 0.816 0.577
0.632 0.707 0.816 1 0.707
0.447 0.5 0.577 0.707 1
sion analysis; mTSS, Medial Tibial Stress Syndrome; SAEs, serious
Table 3 – Overall beneﬁt-risk score and its CI for each treatment option as well as treatment comparisons.
Treatment options Placebo þ MTX Drug 
200 mg þ MTX
Drug 
400 mg þ MTX
δ-Method approach
Overall beneﬁt-risk score (point estimate) 36.2 38.8 32.5
95% CI 18.3–54.0 24.7–52.8 10.7–54.2
Difference in beneﬁt-risk scores between treatment options Mean difference (act. – plb.) 2.57 3.74
95% CI of the difference 20.2 to 25.3 31.9 to 24.4
Pr[B-R act. Better than plb.] 58.8% 39.7%
P (one-sided) 0.412 0.603
Monte-Carlo approach
Overall beneﬁt-risk score (mean) 36.6 40.9 34.3
95% CI 28.5–45.3 31.3–52.7 20.2–49.6
Beneﬁt-risk difference between treatment options Mean difference (act. – plb.) 4.27 2.30
95% CI of the difference 9.51 to 19.4 20.1 to 15.9
Pr[B-R act. Better than plb.] 71.1% 35.7%
P (one-sided) 0.402 0.670
act., the active treatment; B-R, beneﬁt risk; MTX, methotrexate; plb., placebo
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in Table 1, the data of the criterion ACR20 for the treatment option
placebo þ MTX is 11.7% (sample size 100); then, by normal
approximation, the distribution of the parameter is approximately
normal, with mean 0.117 and variance 0.001033 [¼0.117(1  0.117)/
100]. Please note that the parameter distribution refers to the
parameter space (standard error concept), not at the individual
patient level. In addition, because no correlation information and
patient-level data were available, an artiﬁcial correlation matrix
(positive deﬁnite and symmetric), as shown in Table 2, was created
to illustrate that both approaches have the capacity to account for
the correlation among criteria in the MCDA model. In this case
study, for simplicity but without loss of generality, a common
correlation matrix (shown in Table 2) among the criteria in the
MCDA model is used for the three treatment options.
The preference value (also called preference score, utility) for
each criterion in the MCDAmodeling is obtained through the value
function by transforming the corresponding clinical data into aFig. 1 – Value functions of each criterion in the MCDA model. ACR
decision analysis; mTSS, Medial Tibial Stress Syndrome; MTX, meuniﬁed scale. Different criteria may use different value functions.
In general, the value functions for beneﬁts or favorable effects are
designed in such a way that the higher the effect, the greater the
preference (preference value is larger); the value functions for risks
or unfavorable effects are designed in an opposite way in that the
more severe the adverse effect or the higher the risk, the less the
preference. The function types of the value functions could vary,
such as piecewise linear (either linear or inverse linear), quadratic,
and logarithmic. In this case study, the piecewise linear value
functions are used according to the WP3 [13].
Figure 1 plots the value functions for each individual criterion
across the three treatment groups in this case study. For
instance, a linear function as deﬁned in Equation 7 gives the
value function for criterion ACR20 (a beneﬁt or favorable effect)
f ðxÞ ¼
0 xo0
100x 0rxo1
100 xZ1
8><
>: ð7Þ, American College of Rheumatology; MCDA, multiple criteria
thotrexate; pt-yrs, patient-years; SAEs, serious adverse events.
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responders) is the least preferable (preference value ¼ 0) and
100% response rate (all are responders) is the most preferable
(preference value ¼ 100). The response rate of the placebo þ MTX
arm is 11.7%, so its corresponding preference value is 11.7
marked on the plot as symbol “p.” Similarly, the response rate
of the drug X 200 mg þ MTX arm is 58.2%, so its corresponding
preference value is 58.2 marked on the plot as symbol “2.” The
response rate of the drug X 400 mg þ MTX arm is 59.6%, so its
corresponding preference value is 59.6 marked on the plot as
symbol “3.” ACR50 and ACR70 used the same value function as
Equation 7, while mTSS used a slightly different value function,
as shown in Equation 8:
f ðxÞ¼
0 xo0
10x 0rxo10
100 xZ10
8><
>: ð8Þ
However, infections as one of the risk criteria or unfavorable
effects is assigned an inverse linear function, as shown in
Equation 9, as its value function:
f ðxÞ¼
100 xo0:7
1000xþ800 0:7rxo0:8
0 xZ0:8
8><
>: ð9Þ
where x is the incidence rate for the adverse event of infections.
An incidence rate of 80 per 100 patient-years or greater is
considered as the least preferable (preference value ¼ 0) and an
incidence rate of 70 per 100 patient-years or less is considered as
the most preferable (preference value ¼ 100). The incidence rate
of infections in the placebo þ MTX arm is 72.13 per 100 patient-
years, so its corresponding preference value is 78.7 marked on the
plot as symbol “p.” Similarly, the corresponding preference value
for the drug X 200 mg þ MTX arm and the drug X 400 mg þ MTX
arm is 1.2 and 33.8, respectively. The value functions for serious
adverse events, deaths, and tuberculosis are also inverse linear
functions, as shown in Equation 10, Equation 11, and Equation 12,
respectively.
f ðxÞ¼
100 xo0:25
ð2000xþ1200Þ=7 0:25rxo0:6
0 xZ0:6
8><
>: ð10Þ
f ðxÞ¼
100 xo0
ð10000xþ300Þ=3 0rxo0:03
0 xZ0:03
8><
>: ð11Þ
f ðxÞ¼
100 xo0
ð10xþ300Þ=3 0rxo30
0 xZ30
8><
>: ð12Þ
A piecewise inverse linear function, as shown in Equation 13, is
used for the criterion malignancies to model the different
changes in preference value at different data intervals.
f ðxÞ¼
100 xo0
10000xþ100 0rxo0:005
6000xþ80 0:005rxo0:010
3000xþ50 0:010rxo0:015
1000xþ20 0:015rxo0:020
0 xZ0:02
8>>>><
>>>>:
ð13Þ
where x is the adverse event rate of malignancies. The malig-
nancies event rate of 2% or greater is considered as the least
preferable (preference value ¼ 0) and 0% event rate (no adverse
event of malignancies) is considered as the most preferable
(preference value ¼ 100). Then, the preference value for eachtreatment option can be computed by substituting the adverse
event rates into the corresponding segment in Equation 13.
Once the criteria, the data for each criterion, value functions,
and the weights (normalized weights were used in the calcula-
tion) have been determined, the overall beneﬁt-risk score for each
treatment option can be calculated using Equation 1. Table 3
shows the beneﬁt-risk results as well as their conﬁdence inter-
vals obtained by using the δ-method approach and the Monte-
Carlo approach on the basis of data in Tables 1 and 2. It shows
that the overall beneﬁt-risk proﬁles among the treatment options
are relatively close, but the treatment option of drug X 200 mg þ
MTX still has the highest score, indicating the best overall
beneﬁt-risk proﬁle. The conﬁdence intervals based on the
δ-method approach and the Monte-Carlo approach both cover
the overall beneﬁt-risk scores obtained from the observed data,
and the width of the conﬁdence intervals from the δ-method
approach tends to be wider than the ones from the Monte-Carlo
approach. In addition, because of the asymptotic normal approx-
imation, the conﬁdence intervals based on the δ-method
approach are symmetric. The conﬁdence interval from the
Monte-Carlo approach, however, is not necessary to be symmet-
ric. This is not surprising given that the Monte-Carlo approach
uses the simulated true sampling distribution of the overall
beneﬁt-risk score to construct the 95% conﬁdence interval. The
distribution of the overall beneﬁt-risk score is likely to be
asymmetric due to asymmetric or nonlinear value functions
for certain criteria in the MCDA modeling. Figure 2 shows the
boxplot and histograms of the simulated overall beneﬁt-risk
scores for each treatment group. The red crosses and the red
lines indicate the overall beneﬁt-risk scores from the observed
data, which show that although the sampling distributions of the
overall beneﬁt-risk scores for the three treatment options are all
condensed toward the center, they are not necessarily symmet-
ric, and the conﬁdence intervals constructed on the basis of
sampling distributions may not be centered at the overall
beneﬁt-risk scores from the observed data. Figure 3 shows the
density plot of the difference in the overall beneﬁt-risk score
between treatments options. The vertical lines on the plot
indicate the point estimate of the differences in the overall
beneﬁt-risk score based on the observed data for drug X 200 mg
compared with placebo and drug X 400 mg compared with
placebo, respectively.
Table 3 and Figure 2 show that both the δ-method and Monte-
Carlo conﬁdence intervals of the three treatment options are
largely overlapped. Similarly, in Figure 3, both the distribution of
the difference for drug X 200 mg þMTX compared with placebo þ
MTX and the distribution for 400 mg compared with placebo
include 0. This indicates that the overall beneﬁt-risk proﬁles of
the add-on therapy of drug X are probably not signiﬁcantly better
than placebo given the current setting of the MCDA model (the
criteria, the value functions, and the weights). The results are
relatively consistent for both the δ-method approach and the
Monte-Carlo approach while the latter tends to have a higher
precision (narrower conﬁdence interval).Discussion and Conclusions
The MCDA methodology enables comprehensive beneﬁt-risk
assessment among multiple decision criteria and has been
recommended by the EMA in determining the beneﬁt-risk proﬁle
of medicinal products. To account for the randomness from
clinical data and quantify its impact on the MCDA modeling,
two statistical approaches, the δ-method approach and the
Monte-Carlo approach, are proposed in this article. Both
approaches naturally take into account the correlation between
criteria in the MCDA model and are straightforward to
Fig. 2 – Boxplot and histograms of the overall beneﬁt-risk scores for each treatment option. B-R, beneﬁt-risk; MTX,
methotrexate.
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as well as a series of probabilistic or statistical measures pro-
duced using the proposed methods, are helpful for statistical
inference and communication in beneﬁt-risk assessment.50 0 50 100
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Fig. 3 – Density plot of the difference in the overall beneﬁt-
risk scores between treatment options. B-R, beneﬁt-risk;
plb., placebo.The δ-method approach is straightforward and has a closed
form (Equation 2) to quickly quantify the variance of the overall
beneﬁt-risk score from the MCDA model. The Monte-Carlo
approach is more computationally intensive but could provide
any desired probabilistic or statistical measures directly for
statistical inference because the true sampling distributions of
the overall beneﬁt-risk scores are available through simulation.
Both approaches impose an asymptotically multivariate normal
assumption to preserve the correlation structure between the
clinical parameters (criteria) in the MCDA model. The difference
is that the δ-method approach further applies the asymptotically
normal approximation on the overall beneﬁt-risk score to quan-
tify its variability whereas the Monte-Carlo approach uses prob-
abilistic simulation to assemble the true sampling distribution of
the overall beneﬁt-risk score. Therefore, both approaches yield
fairly consistent results under the moderate to large sample size
situation (e.g., about a hundred subjects or more per treatment
group, which is commonly seen in late drug development stage).
Because the δ-method approach, however, produces a symmetric
conﬁdence interval that might artiﬁcially increase the width of
the interval, the conﬁdence interval produced by the Monte-Carlo
approach tends to be narrower (or more precise). But such
difference becomes smaller as the sample size increases.
Table 4 was obtained on the basis of same criteria and param-
eters as in Table 3 except that the sample size of each criterion in
the MCDA model was made roughly 10 times larger. As expected,
when the sample size is increased, the results from the δ-method
approach and the Monte-Carlo approach get closer. Similarly,
Figures 4 and 5, like Figure 2 and 3, show that the shapes of the
sampling distributions of the overall beneﬁt-risk scores for each
treatment option as well as their differences between treatment
Table 4 – Overall beneﬁt-risk score and its CI for each treatment option as well as treatment comparisons with
large sample size.
Treatment options Placebo þ MTX Drug 
200 mg þ MTX
Drug 
400 mg þ MTX
δ-Method approach
Overall beneﬁt-risk score (point estimate) 36.2 38.8 32.5
95% CI 30.8–41.8 33.8–43.7 24.4–40.5
Difference in beneﬁt-risk scores between treatment options Mean difference (act. – plb.) 2.57 3.74
95% CI of the difference 4.89 to 10.0 13.5 to 6.1
Pr[B-R act. Better than plb.] 75.0% 22.8%
P (one-sided) 0.250 0.772
Monte-Carlo approach
Overall beneﬁt-risk score (mean) 36.3 39.4 33.2
95% CI 32.0–41.4 35.9–44.1 27.2–41.2
Beneﬁt-risk difference between treatment options Mean difference (act. – plb.) 3.08 3.15
95% CI of the difference 3.07 to 9.45 10.9 to 6.07
Pr[B-R act. Better than plb.] 83.5% 22.9%
P (one-sided) 0.258 0.803
act., the active treatment; B-R, beneﬁt risk; MTX, methotrexate; plb., placebo.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 1 9 – 6 2 8626options are narrower and appear to be more normally distributed
when the sample size is increased. This suggests that for large
sample size situation (e.g., hundreds to thousands of subjects),
the δ-method approach actually could work quite well. It should
also be recognized that the performance of the δ-method
approach or the Monte-Carlo approach depends on the viability
of the asymptotically multivariate normal assumption used in
both approaches. In the situation of either small sample size orFig. 4 – Boxplot and histograms of the overall beneﬁt-risk scores
data. B-R, beneﬁt-risk; MTX, methotrexate.rare event case (e.g., severe but rare risk outcome) when the
normal approximation assumption is not well held, certain non-
parametric methods or data-transformation techniques (e.g.,
rank correlation, or log-transformation for skewed data) might
be required before applying the two approaches for MCDA
analysis.
Both the δ-method approach and the Monte-Carlo approach
proposed in this article are based on study-level summaryfor each treatment group with larger sample size of clinical
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Fig. 5 – Density plot of the difference in the overall beneﬁt-
risk scores between treatment options with larger sample
size of clinical data. B-R, beneﬁt-risk; plb., placebo.
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Carlo approach may completely reduce the parametric
(i.e., asymptotically normal) assumption by using the bootstrap
method and at the same time preserve the correlation structure
between the criteria in the MCDA model as much as possible. The
bootstrap method could be conducted in the following three
steps. First, resample from the patient-level data directly to
create the bootstrapped sample data set. Second, for each boot-
strapped sample data set calculate the summary statistics (e.g.,
mean) by each criterion in the MCDA model. This yields the joint
bootstrapped sampling distribution of the criteria in the MCDA
model (in the parameter space). Third, for each set of the sample
from the joint distribution generated in the previous step,
repeatedly apply Equation 1 to obtain the sampling distribution
of the overall beneﬁt-risk score as well as other desired proba-
bilistic or statistical measures for comparing the beneﬁt-risk
proﬁle of different treatment options.
Bayesian methods have also appeared in the literature for
quantifying the probabilistic uncertainty of the overall beneﬁt-
risk score [16,28]. One type of the Bayesian methods related to
MCDA we referred to [16] is similar to the Monte-Carlo approach
proposed in this article. It ﬁrst generates random samples from
the posterior distributions of each individual criterion in the
MCDA model. The posterior distributions are derived on the basis
of priors of the clinical parameters and the observed data. Then,
those simulated random samples of each criterion are substi-
tuted into the MCDA model to obtain the true sampling distribu-
tion of the overall beneﬁt-risk score. Once the distribution is
obtained, statistical inference can be made. Compared with the
two Frequentist approaches proposed in this article, which use
only the observed data in the analysis, the merit of the Bayesian
method is the ability to incorporate prior information into the
MCDA model. The Bayesian method as used in the literature [16],
however, only simulated random samples independently by each
criterion without accounting for the correlation between criteria
in the MCDA model; hence, the information on how the clinical
criteria in the MCDA model were correlated with each other was
lost. To incorporate such correlation structure into the model, it
might require a more sophisticated Bayesian modeling, whichmay be for future research and out of scope of this article.
Moreover, the prior distribution used in the Bayesian method
may introduce more parameters and subjectivity in MCDA
modeling unless noninformative priors are used, in which case
the Bayesian method may be similar to the Frequentist method.
The proposed methods did not aim to address the uncertainty
associated with the criteria selection and weighting in MCDA
modeling, but rather provide a way for probabilistic sensitivity
analysis to incorporate the variability from the clinical data when
the MCDA is used for the beneﬁt-risk assessment of medicinal
products. Although statistical thinking and quantitative analyses
in beneﬁt-risk decision making are critical, it is also true that a
single number or a few numbers from any model cannot
completely replace human judgment. Thus, the overall beneﬁt-
risk score with its associated conﬁdence intervals and other
probabilistic or statistical measures (e.g., P value, median, and
probabilities) is considered more for communication purposes
than for inferential purposes. These quantities could serve as
references and better facilitate the discussion on the beneﬁt-risk
proﬁles of different treatment options among regulatory agen-
cies, policymakers, senior executives/management of companies,
and the public audience in general.Acknowledgments
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